Breast Cancer

The US Food and Drug Administration recently approved alpelisib plus fulvestrant for the treatment of metastatic or otherwise advanced breast cancer.

Highlights of breast cancer advances at the ESMO Congress.

Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Biosimilars have shown to be cost-effective treatments in oncology and hematology, according to Jacopo Giuliani, MD.

MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions.

Treatment with trastuzumab emtansine demonstrated similar overall survival across 3 treatment arms of patients with HER2‐positive metastatic breast cancer.

A blood test which may detect the traces of developing breast cancer through autoantibodies years before clinical signs show themselves is now proposed by researchers in the United Kingdom.

Dr. Allison W. Kurian discusses a new breast cancer study that analyzed the mutations present in breast tumors, and about emerging targeted therapy options.

A new study examined differences in breast cancer recurrence and survival by region.

High testosterone and low folate intake together may drastically increase risk of breast cancer.

Patients, providers, and healthcare processes benefit from systematically collecting patient-reported outcomes and reviews of their experiences in breast cancer treatment.

Two trials and 3000 patients with HER2-positive breast cancer were analyzed for recurrence risk 5 to 10 years after diagnosis.

Tucatinib showed improvements in survival in patients with HER2-positive breast cancer.

The results of this new study could also further explain the patterns of tumor development among certain ethnicities.

Radiologists and data scientists decided to get together to evaluate the effectiveness of artificial intelligence and human observation when it comes to detecting breast cancer in mammograms.

For the first time, researchers have isolated a subtype of gamma-delta T-cells that offers protection in women with triple-negative breast cancer.

The combination of trilaciclib and chemotherapy was generally well–tolerated with promising activity in a phase II trial of patients with metastatic triple-negative breast cancer.

New guidelines for exercise for patients with cancer have been released.

The combined use of a CDK4/6 inhibitor with endocrine therapy yielded a 9.4-month median OS benefit among patients.

CancerNetwork® spoke with Dr. Sara Hurvitz, associate professor of medicine at the University of California, Los Angeles, about therapy options for breast cancer. 

The agency is set to make a decision on the investigational antibody drug conjugate by the first quarter of 2020.

CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.

Several clinicopathologic features of HER2-positive breast cancer patients were found to be associated with response to neoadjuvant therapy in a new study.

A new study looked at the characteristics of diagnosed breast cancer cases in San Francisco.

Serena Nik-Zainal, MD, discusses study findings that could change the way treatment strategies for subgroups of patients with triple-negative breast cancer are evaluated.